<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The demonstration that fibrillin-1 mutations perturb transforming growth factor (TGF)-β bioavailability/signaling in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) changed the view of the extracellular matrix as a passive structural support to a dynamic modulator of cell behavior </plain></SENT>
<SENT sid="1" pm="."><plain>In this issue, Nistala et al </plain></SENT>
<SENT sid="2" pm="."><plain>(2010 </plain></SENT>
<SENT sid="3" pm="."><plain>J </plain></SENT>
<SENT sid="4" pm="."><plain>Cell Biol. doi: 10.1083/jcb.201003089) advance this concept by demonstrating how fibrillin-1 and -2 regulate TGF-β and bone morphogenetic protein (BMP) action during osteoblast maturation </plain></SENT>
</text></document>